SEC Filing Summary: Prima BioMed Ltd (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Prima BioMed Ltd, a foreign private issuer headquartered in Sydney, Australia, on July 11, 2013. The filing serves as a report pursuant to Rule 13A-16 under the Securities Exchange Act of 1934. The document primarily contains a response to an ASX Price Query letter (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document is a procedural response to a regulatory query and does not contain a financial statement or performance summary.
Material Changes
No material changes in financial position or operations are detailed in the provided text. The filing focuses on the submission of a response to the Australian Securities Exchange (ASX) rather than reporting operational or financial variances.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, future guidance, risk factors, or details regarding contingencies and unusual items. The content is limited to the administrative submission of the ASX response.
Investor Verification Checklist
- Verify the content of the "Response to ASX Price Query letter" (Exhibit 99.1) to understand the specific regulatory inquiry addressed.
- Confirm the company's current ticker symbol and listing status, noting the discrepancy between the company name in the metadata (IMMUTEP Ltd) and the registrant name in the filing (Prima BioMed Ltd).
- Review subsequent Form 20-F filings for detailed financial performance data not included in this report.